ERBB2 and breast carcinoma: Evidence is accumulating that naturally occurring immunity is present in patients with breast cancer against tumor associated antigens such as HER-2/neu [2,3] and cdr2 [4], as well as the antigens investigated here, namely MUC-1 [5,6], cyclin B1 [7] and survivin [8].